Home » News » At Least Two Deaths Have Been Connected to an Alzheimer's Treatment Experiment

At Least Two Deaths Have Been Connected to an Alzheimer's Treatment Experiment

(Image Credit Google)
An investigational report published this week suggests that an experimental treatment for Alzheimer's disease may pose a life-threatening risk of brain bleeding in certain patients. The study, published in the journal Science on Monday, describes the death of a 65-year-old woman from massive hemorrhaging that could have been caused by having a common blood thinner while on the experimental treatment. The incident is assumed to be the second similar death related to the treatment, which will be evaluated for FDA approval early next year. [caption id="attachment_67141" align="aligncenter" width="564"]Consulting with doctor Image: NIH[/caption] The treatment, known as lecanemab, is being developed collaboratively by the pharma firms Biogen and Eisai. It's a lab-created antibody designed to target amyloid beta, a protein thought to play a critical role in Alzheimer's disease. It's a lab-created antibody designed to target amyloid beta, a protein thought to play a key role in Alzheimer's disease. Plaques, which are tough, toxic clumps of amyloid that form throughout the brain in Alzheimer's patients, damage it over time. The drug primarily attempts to break down amyloid deposits that have not yet formed these plaques, which should, in theory, stop or slow the progression of Alzheimer's symptoms. [caption id="attachment_67144" align="aligncenter" width="673"]alzheimers Image: pathdoc/Shutterstock.com[/caption] Researchers published what emerged to be the first large-scale trial of an anti-amyloid drug earlier this year. She had taken in the initial 18-month trial, though most likely as a placebo participant. Her family removed her life assistance a few days later, with no evident hope of recovery. According to new research, Alzheimer's drugs may have weakened amyloid deposits near blood vessels, resulting in brain bleeding in patients who took them. If this is true, it could prompt explicit warning labels to be attached to these drugs in the future. Many elderly people at risk of Alzheimer's must take blood thinners to cure or manage other health problems, such as stroke. Most previous drugs in this class have failed major clinical trials outright, which included a candidate that failed in trials. The FDA is expected to decide on its approval in January of next year.

By Raulf Hernes

If you ask me raulf means ALL ABOUT TECH!!

RELATED NEWS

(Image credit- According to a peer-reviewed stu...

news-extra-space

(Image credit- NPR) An AI voice assistant softw...

news-extra-space

(Image credit- Forbes) Are you worried about th...

news-extra-space

The Health Care Benefits of Combining Wearables ...

news-extra-space

Photo Credit: Gizmochina For the Mijia Smart Ai...

news-extra-space
2
3
4
5
6
7
8
9
10